浏览全部资源
扫码关注微信
- Journal Information
- Archive
- Submission
- For Reviewers
- Statement and Policies
Application of gene detection in individualized treatment of lipid-lowering drugs
- ZHONGGUO YAOFANG Vol. 34, Issue 9, Pages: 1147-1152(2023)
- 作者机构：
1.南华大学药物药理研究所，湖南 衡阳 421000
2.南华大学附属南华医院临床药学研究所，湖南 衡阳 421000
- 作者简介：
- 基金信息：
DOI：10.6039/j.issn.1001-0408.2023.09.23
CLC： R972+.6;Q343.1+2Published：15 May 2023，
Received：20 October 2022，
Revised：24 March 2023，
扫 描 看 全 文
朱扬媚,曹建刚,周玉生.基因检测在降脂药物个体化治疗中的应用 Δ[J].中国药房,2023,34(09):1147-1152.
ZHU Yangmei,CAO Jiangang,ZHOU Yusheng.Application of gene detection in individualized treatment of lipid-lowering drugs[J].ZHONGGUO YAOFANG,2023,34(09):1147-1152.
朱扬媚,曹建刚,周玉生.基因检测在降脂药物个体化治疗中的应用 Δ[J].中国药房,2023,34(09):1147-1152. DOI： 10.6039/j.issn.1001-0408.2023.09.23.
ZHU Yangmei,CAO Jiangang,ZHOU Yusheng.Application of gene detection in individualized treatment of lipid-lowering drugs[J].ZHONGGUO YAOFANG,2023,34(09):1147-1152. DOI： 10.6039/j.issn.1001-0408.2023.09.23.
摘要
血脂异常在临床上主要表现为高脂血症，是导致动脉粥样硬化、冠心病和脑卒中等心脑血管疾病发生的重要危险因素。临床上主要采用降脂药物进行治疗，但存在个体差异、基因影响等问题。因此，有必要对患者进行基因检测，从而指导降脂药物的个体化应用。本文主要对基因检测的定义和降脂药物的个体化治疗进行了概述，并介绍了基因检测在降脂药物（他汀类、贝特类、烟酸和依折麦布）个体化治疗方面的应用。其中
APOE
、
SLCO1B1
和
CYP450
家族的基因多态性对他汀类药物的疗效和安全性起到关键作用，
APOA/B/C
家族基因多态性对非诺贝特的疗效有显著影响，
HCAR2
和
DGAT2
基因多态性对烟酸的疗效具有重要影响，
NPC1L1
基因多态性对依折麦布的疗效影响较大。建议对血脂异常的患者进行基因检测，以选择合适的治疗策略，从而进行个体化用药指导。
Abstract
The main clinical manifestation of dyslipidemia is hyperlipidemia， which is an important risk factor leading to the occurrence of cardiovascular and cerebrovascular diseases such as atherosclerosis， coronary heart disease and stroke. In clinical practice， lipid-lowering drugs are mainly used for treatment， but there are issues such as individual differences and genetic effects. Therefore， it is necessary to perform gene detection on patients， so as to guide individualized application of lipid-lowering drugs. This review mainly previews the definition of gene detection and the individualized treatment of lipid-lowering drugs， and introduces the application of gene detection in the individualized treatment of lipid-lowering drugs （statins， fibrates， nicotinic acid and ezetimibe）. Among them， the gene polymorphisms of
APOE
，
SLCO1B1
and
CYP450
family play a key role in the efficacy and safety of statins； the gene polymorphisms of
APOA/B/C
family have a significant impact on the efficacy of fenofibrate； the gene polymorphisms of
HCAR2
and
DGAT2
have an important impact on the efficacy of niacin； the gene polymorphisms of
NPC1L1
have a significant impact on the efficacy of ezetimibe. It is suggested to conduct genotype detection for patients with dyslipidemia to select appropriate treatment strategies， so as to provide individualized medication guidance.
关键词
基因检测降脂药物个体化治疗基因多态性
Keywords
lipid-lowering drugsindividualized treatmentgene polymorphism
references
PAN L L，TIAN Y，SUN H Y，et al. TMT-based proteomics analysis reveals the efficacy of Jiangzhuo formula in improving the lipid profiles of dyslipidemia rats[J]. J Ethnopharmacol，2021，264：113390.
LEGAULT M A，TARDIF J C，DUBÉ M P. Pharmacogenomics of blood lipid regulation[J]. Pharmacogenomics，2018，19（7）：651-665.
GRUNDY S M，STONE N J，BAILEY A L，et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol：a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines[J]. Circulation，2019，139（25）：e1082-e1143.
Cholesterol Treatment Trialists’ （Ctt） Collaboration，BAIGENT C，BLACKWELL L，et al. Efficacy and safety of more intensive lowering of LDL cholesterol：a meta-analysis of data from 170 000 participants in 26 rando- mised trials[J]. Lancet，2010，376（9753）：1670-1681.
WEINSHILBOUM R M，WANG L W. Pharmacogeno- mics：precision medicine and drug response[J]. Mayo Clin Proc，2017，92（11）：1711-1722.
侯英勇，钱梦佳，程韵枫，等. 基因检测在精准医疗中的应用与管理[J]. 中国临床医学，2022，29（1）：7-10.
MACH F，BAIGENT C，CATAPANO A L，et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias：lipid modification to reduce cardiovascular risk[J]. Eur Heart J，2020，41（1）：111-188.
ROSSI M，FABRIS E，BARBISAN D，et al. Lipid-lowering drug therapy：critical approach for implementation in clinical practice[J]. Am J Cardiovasc Drugs，2022，22（2）：141-155.
RODEN D M，MCLEOD H L，RELLING M V，et al. Pharmacogenomics[J]. Lancet，2019，394（10197）：521-532.
OSANLOU O，PIRMOHAMED M，DALY A K. Pharmaco- genetics of adverse drug reactions[J]. Adv Pharmacol，2018，83：155-190.
ARBITRIO M，SCIONTI F，DI MARTINO M T，et al. Pharmacogenomics biomarker discovery and validation for translation in clinical practice[J]. Clin Transl Sci，2021，14（1）：113-119.
HESS G，CHANG C L，CHUNG K. Lipid attainment among patients newly treated with lipid-altering drugs[J]. Curr Med Res Opin，2014，30（9）：1743-1756.
蔡晓彤，游璎琦，杨欣. 他汀类药物个体化用药研究进展[J]. 实用药物与临床，2021，24（10）：950-955.
JABR R，GHARAIBEH M，ZAYED A A，et al. The association between apolipoprotein E polymorphism and response to statins in group of hyperlipidemic patients[J]. Endocr Metab Immune Disord Drug Targets，2021，21（4）：720-725.
伏开全，李群星，尹德录，等. 载脂蛋白E基因多态性检测对ACS患者降脂疗效的影响[J]. 现代生物医学进展，2021，21（6）：1191-1195.
高辉，王杨，陈婉婷，等. SLCO1B1和APOE基因多态性与他汀类药物疗效的相关性[J]. 实用医学杂志，2019，35（14）：2300-2303.
王凤玲，孟祥云，陈正徐，等. 安徽地区汉族心血管疾病患者SLCO1B1与ApoE基因多态性分布及其在他汀类药物临床个体化应用中的意义[J]. 中国临床药理学与治疗学，2021，26（1）：40-48.
刘龙梅，王仲朝，张颖，等. SLCO1B1521 T＞C/ApoE基因多态性对阿托伐他汀临床应用的研究[J]. 中西医结合心脑血管病杂志，2020，18（2）：303-306.
XIANG Q，CHEN S Q，MA L Y，et al. Association between SLCO1B1 T521C polymorphism and risk of statin-induced myopathy：a meta-analysis[J]. Pharmacogenomics J，2018，18（6）：721-729.
刘若轩，何皓颋，邓志军，等. 冠心病患者基因多态性对脂溶性他汀类药物降脂作用的影响[J]. 中南药学，2020，18（10）：1772-1775.
SIVKOV A，CHERNUS N，GORENKOV R，et al. Relationship between genetic polymorphism of drug transpor- ters and the efficacy of rosuvastatin，atorvastatin and simvas- tatin in patients with hyperlipidemia[J]. Lipids Health Dis，2021，20（1）：157.
李居怡，王健，王奕，等. 他汀类药物降脂治疗的CYP2D6基因多态性及其与高脂血症的关系[J]. 实用医学杂志，2016，32（2）：207-210.
LIU N，YANG G H，LIU Y P，et al. Effect of cytochrome P450 7A1 （CYP7A1） polymorphism on lipid responses to simvastatin treatment[J]. J Cardiovasc Pharmacol，2020，75（2）：168-173.
SAŁACKA A，BOROŃ A，GORĄCY I，et al. An association of ABCG8：rs11887534 polymorphism and HDL-cholesterol response to statin treatment in the Polish population[J]. Pharmacol Rep，2021，73（6）：1781-1786.
LIU M Y，FAN F F，ZHANG Y，et al. The association of GATM polymorphism with statin-induced myopathy：a systematic review and meta-analysis[J]. Eur J Clin Pharmacol，2021，77（3）：349-357.
CHAPMAN M J. Fibrates in 2003：therapeutic action in atherogenic dyslipidaemia and future perspectives[J]. Atherosclerosis，2003，171（1）：1-13.
HOUSE J S，MOTSINGER-REIF A A. Fibrate pharmaco- genomics：expanding past the genome[J]. Pharmacogenomics，2020，21（4）：293-306.
LIU Y J，ORDOVAS J M，GAO G M，et al. Pharmaco- genetic association of the APOA1/C3/A4/A5 gene cluster and lipid responses to fenofibrate：the genetics of lipid-lowering drugs and diet network study[J]. Pharmacogenet Genomics，2009，19（2）：161-169.
WOJCZYNSKI M K，GAO G M，BORECKI I，et al. Apolipoprotein B genetic variants modify the response to fenofibrate：a GOLDN study[J]. J Lipid Res，2010，51（11）：3316-3323.
TSAI M Y，ORDOVAS J M，LI N，et al. Effect of fenofibrate therapy and ABCA1 polymorphisms on high-density lipoprotein subclasses in the Genetics of Lipid Lowering Drugs and Diet Network[J]. Mol Genet Metab，2010，100（2）：118-122.
LIU Y J，ORDOVAS J M，GAO G M，et al. The SCARB1 gene is associated with lipid response to dietary and pharmacological interventions[J]. J Hum Genet，2008，53（8）：709-717.
SHEN J，ARNETT D K，PARNELL L D，et al. The effect of CYP7A1 polymorphisms on lipid responses to fenofibrate[J]. J Cardiovasc Pharmacol，2012，59（3）：254-259.
CARLSON L A. Nicotinic acid：the broad-spectrum lipid drug. A 50th anniversary review[J]. J Intern Med，2005，258（2）：94-114.
ASLIBEKYAN S，STRAKA R J，IRVIN M R，et al. Pharmacogenomics of high-density lipoprotein-cholesterol- raising therapies[J]. Expert Rev Cardiovasc Ther，2013，11（3）：355-364.
TUTEJA S，WANG L，DUNBAR R L，et al. Genetic coding variants in the niacin receptor，hydroxyl-carboxylic acid receptor 2，and response to niacin therapy[J]. Pharmacogenet Genomics，2017，27（8）：285-293.
ZHANG L H，KAMANNA V S，GANJI S H，et al. Niacin increases HDL biogenesis by enhancing DR4-dependent transcription of ABCA1 and lipidation of apolipoprotein A-I in HepG2 cells[J]. J Lipid Res，2012，53（5）：941-950.
HU M，CHU W C，YAMASHITA S，et al. Liver fat reduction with niacin is influenced by DGAT-2 polymorphisms in hypertriglyceridemic patients[J]. J Lipid Res，2012，53（4）：802-809.
HU M，YANG Y L，NG C F，et al. Effects of phenotypic and genotypic factors on the lipid responses to niacin in Chinese patients with dyslipidemia[J]. Medicine （Baltimore），2015，94（20）：e881.
BAE J W，CHOI C I，LEE J H，et al. Effects of UDP-glucuronosyltransferase polymorphisms on the pharmacokinetics of ezetimibe in healthy subjects[J]. Eur J Clin Pharmacol，2011，67（1）：39-45.
ALTMANN S W，JrDAVIS H R，ZHU L J，et al. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption[J]. Science，2004，303（5661）：1201-1204.
LOU X Y，QIN C Z，BAO M H，et al. Analysis of Niemann-Pick C1-like 1 （NPC1L1） genetic polymorphisms and haplotypes in Chinese Han population[J]. Pharmazie，2015，70（9）：581-585.
ZSÍROS N，BODOR M，VARGA V，et al. The c.-133A ＞ G polymorphism in NPC1L1 gene influences the efficacy of ezetimibe monotherapy on apolipoprotein A1 in hyperlipidemic patients[J]. Pharmazie，2014，69（6）：424-429.
PISCIOTTA L，FASANO T，BELLOCCHIO A，et al. Effect of ezetimibe coadministered with statins in genotype-confirmed heterozygous FH patients[J]. Atherosclerosis，2007，194（2）：e116-e122.
BERTHOLD H K，LAAKSONEN R，LEHTIMÄKI T， et al. SREBP-1c gene polymorphism is associated with increased inhibition of cholesterol-absorption in response to ezetimibe treatment[J]. Exp Clin Endocrinol Diabetes，2008，116（5）：262-267.
KAWAMURA R，SAIKI H，TADA H，et al. Acute myocardial infarction in a 25-year-old woman with sitosterolemia[J]. J Clin Lipidol，2018，12（1）：246-249.
TADA H，NOHARA A，INAZU A，et al. Sitosterolemia，hypercholesterolemia，and coronary artery disease[J]. J Atheroscler Thromb，2018，25（9）：783-789.
0
Views
10
下载量
0
CSCD
- L-PDFDownload
- WORDDownload
- Meta-XMLDownload
- BibTeXDownload
- EndnoteDownload
- RefMan Download
- NoteExpressDownload
- NoteFirstDownload
Publicity Resources
Related Articles
Related Author
Related Institution
- Address：8/F,129 Daping Main Street,Yuzhong District,Chongqing 400042,P.R.China
- Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号
公网安备50010302001817 - It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
- Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.